"From a coding standpoint and from the work performed and valuation of the work and descriptors, it is appropriate to report the dilation (50436 without or 50437 with new access as appropriate) along with the nephrolithotomy codes (50080/50081) when both are performed at the same time by the same provider," write Jonathan Rubenstein, MD, and Mark Painter.
According to the authors, these findings highlight the need to more effectively include Black men in prostate cancer research.
If approved, the marketing authorization application would be valid in all 27 European Union member states as well as in Iceland, Liechtenstein, and Norway.
“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.
"Please note that although this starts out as a balloon rather than just the injection of a biodegradable product, this device is actually fully biodegradable and is absorbed within 6 months of insertion," write Jonathan Rubenstein, MD, and Mark Painter.
64Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.
Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.
At 25 weeks, FACT-P total score remained comparable between the arms.
"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.
"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.
The accuracy of PLND was 93.41% in the ICG injection arm compared with 75.91% in the control arm.
The median time to correct treatment was 98 days with initial TURBT compared with 53 days with initial mpMRI.
Functional success was achieved in 58% of patients at 5-year follow-up.
At a median follow-up of 24.3 months, the confirmed objective response rate was 70%.
"There are far more people presenting to us for care than we have people able to provide it. The APPs are going to be a critical part of trying to solve that puzzle," says Mark T. Edney, MD.
The 15 drugs identified in this round of negotiations add to the 10 selected in the first round of negotiations that took place in 2023 and 2024.
The European approval of Illuccix adds on to prior approvals in the US, Australia, and Canada.
“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.
In total, 40.3% of patients experienced a change in staging between initial assessment on conventional imaging and PSMA PET.
The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.
The NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.
The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.
“In this phase 2 study, an image-guided adaptive strategy enabled radiotherapy dose escalation to over 86% of patients’ bladder tumors without significant increase in toxicity,” wrote the authors.
In a recent study of the RELIEF stent, 95% of patients showed no VUR following stent placement.
The PDUFA target action date has been set for August 29, 2025.
The Expander-2 trial is intended to provide data that will support submission of the device for regulatory approval.
"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.
The test can provide results in 48 minutes for diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital syndromes.
Results from CREST will be presented at an upcoming medical conference.
"We expect to initiate patient dosing in the second quarter of this year, with initial three-month [complete response] data to follow," says Doug Warner.
